Gabapentin vs Leqembi
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Gabapentin | US Leqembi | |
|---|---|---|
| Generic name | gabapentin | lecanemab |
| Drug class | Anticonvulsant / Nerve Pain Agent | Anti-Amyloid Monoclonal Antibody |
| Treats | Nerve pain, seizures | Early Alzheimer's disease |
| Category | Neurology | Neurology |
| Manufacturer | Various (generic) | Eisai |
| Year approved | 1993 | 2023 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $1M | — |
| Common side effects | Drowsiness, Dizziness, Swelling, Coordination problems | Brain swelling (ARIA), Brain bleeding (ARIA), Infusion reactions, Headache |
Gabapentin
Frequently asked questions
Is Gabapentin or Leqembi better?
Neither is universally "better." Gabapentin (gabapentin) and Leqembi (lecanemab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Gabapentin and Leqembi?
Gabapentin is a Anticonvulsant / Nerve Pain Agent made by Various (generic), while Leqembi is a Anti-Amyloid Monoclonal Antibody made by Eisai. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Gabapentin has the larger estimated TV advertising budget of the two.